Evaluation of breast cancer stem cells in human primary breast carcinoma and their role in aggressive behavior of the disease
Background & aim: To delineate the underlying molecular mechanisms responsible for the intratumoral enrichment of BCSCs in aggressive breast tumors, we evaluated the frequency and characteristics of breast cancer stem cells (BCSCs) within the tumor tissue in primary human breast carcinomas. We assessed the expression profiles of various genes in cancer cells and stromal cells from these tumors to delineate the role played by the cellular niche in de novo origin or expansion of intra-tumoral cancer stem cells.
Method: The study included primary tumor and adjacent normal breast tissue specimens from chemotherapy-naïve breast carcinoma patients. The BCSCs, identified as Lin-CD44+CD24- and aldehyde dehydrogenase 1 A1 positive, were enumerated. The flow-cytometrically sorted stromal, and cancer cells were processed for gene expression profiling using a custom-designed PCR array of genes known to facilitate disease progression.
Results: The frequency of BCSCs within the tumor mass correlated significantly with histopathological and molecular grades of tumors, indicating a direct relationship of BCSC with the aggressive behavior of breast cancer. Further, a significantly increased expression of the genes associated with growth factors, cytokines & matricellular proteins in tumors was found in high BCSCs compared to Lo-BCSC tumors, suggesting the possible contribution of stromal and cancer cells in an intratumoral expansion of CSCs. Similarly, a significant up-regulation of genes associated with hypoxia and angiogenesis in Hi-BCSCs tumors further supported the role of a hypoxic environment.
Conclusion: Overall, the findings suggest the molecular crosstalk between stromal cells and cancer cells potentially (directly or indirectly) contributes to the expansion of cancer stem cells.
Relevance for patients: The current study highlights the importance of cancer stem cells as a potential future predictive/prognostic marker for aggressive breast cancer. The present study predicts the potential risk stratification based on the frequency of BCSCs in primary breast tumors and existing prognostic factors.
[1] Senda N, Yamaguchi A, Nishimura H, Shiozaki T, Tsuyuki S. Pertuzumab, Trastuzumab, and Docetaxel Reduced the Recurrence of Brain Metastasis from Breast Cancer: A Case Report. Breast Cancer 2016;23:323-8.
[2] Zekri J, Mokhtar M, Karim SM, Darwish T, Al-Foheidi M, Rizvi A, et al. Lapatinib-Based Therapy for Women with Advanced/Metastatic HER2 Positive Breast Cancer. Exp Oncol 2015;37:146-50.
[3] Cardoso F, Harbeck N, Fallowfield L, Kyriakides S, Senkus E, ESMO Guidelines Working Group. Locally Recurrent or Metastatic Breast Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and FollowUp. Anna Oncol 2012;23 Suppl 7:vii11-9.
[4] Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, et al. Residual Breast Cancers after Conventional Therapy Display Mesenchymal as Well as Tumor-Initiating Features. Proc Natl Acad Sci USA 2009;106:13820-5.
[5] Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, et al. Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy. J Natl Cancer Inst 2008;100:672-9.
[6] Sin WC, Lim CL. Breast Cancer Stem Cells-from Origins to Targeted Therapy. Stem Cell Invest 2017;4:96. [7] Ailles LE, Weissman IL. Cancer Stem Cells in Solid Tumors. Curr Opin Biotechnol 2007;18:460-6.
[8] Cazet AS, Hui MN, Elsworth BL, Wu SZ, Roden D, Chan CL, et al. Targeting Stromal Remodeling and Cancer Stem Cell Plasticity Overcomes Chemoresistance in TripleNegative Breast Cancer. Nat Commun 2018;9:2897.
[9] Moitra K. Overcoming Multidrug Resistance in Cancer Stem Cells. Biomed Res Int 2015;2015:635745.
[10] Baig S, Seevasant I, Mohamad J, Mukheem A, Huri HZ, Kamarul T. Potential of Apoptotic Pathway-Targeted Cancer Therapeutic Research: Where Do We Stand? Cell Death Dis 2016;7:e2058.
[11] Phi LTH, Sari IN, Yang YG, Lee SH, Jun N, Kim KS, et al. Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment. Stem Cells Int 2018;2018:5416923.
[12] Abraham BK, Fritz P, McClellan M, Hauptvogel P, Athelogou M, Brauch H. Prevalence of CD44+/CD24-/ Low Cells in Breast Cancer May not be Associated with Clinical Outcome but May Favor Distant Metastasis. Clin Cancer Res 2005;11:1154-9.
[13] Ahmed MA, Aleskandarany MA, Rakha EA, Moustafa RZ, Benhasouna A, Nolan C, et al. A CD44(-)/CD24(+) Phenotype is a Poor Prognostic Marker in Early Invasive Breast Cancer. Breast Cancer Res Treat 2012;133:979-95.
[14] Albini A, Bruno A, Gallo C, Pajardi G, Noonan DM, Dallaglio K. Cancer Stem Cells and the Tumor Microenvironment: Interplay in Tumor Heterogeneity. Connect Tissue Res 2015;56:414-25.
[15] Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective Identification of Tumorigenic Breast Cancer Cells. Proc Natl Acad Sci USA 2003;100:3983-8.
[16] Lacina L, Plzak J, Kodet O, Szabo P, Chovanec M, Dvorankova B, et al. Cancer Microenvironment: What Can We Learn from the Stem Cell Niche. Int J Mol Sci 2015;16:24094-110.
[17] Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, ZhouAY, et al. The epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells. Cell 2008;133:704-15.
[18] Wang SS, Jiang J, Liang XH, Tang YL. Links between Cancer Stem Cells and Epithelial-Mesenchymal Transition. Onco Targets Ther 2015;8:2973-80.
[19] Scheel C, Eaton EN, Li SH, Chaffer CL, Reinhardt F, Kah KJ, et al. Paracrine and Autocrine Signals Induce and Maintain Mesenchymal and Stem Cell States in the Breast. Cell 2011;145:926-40.
[20] Mukherjee S, Manna A, Bhattacharjee P, Mazumdar M, Saha S, Chakraborty S, et al. Non-Migratory Tumorigenic Intrinsic Cancer Stem Cells Ensure Breast Cancer Metastasis by Generation of CXCR4(+) Migrating Cancer Stem Cells. Oncogene 2016;35:4937-48.
[21] Garner EF, Beierle EA. Cancer Stem Cells and Their Interaction with the Tumor Microenvironment in Neuroblastoma. Cancers (Basel) 2015;8:5.
[22] Shiozawa Y, Nie B, Pienta KJ, Morgan TM, Taichman RS. Cancer Stem Cells and their Role in Metastasis. Pharmacol Ther 2013;138:285-93.
[23] Bao B, Ahmad A, Azmi AS, Ali S, Sarkar FH. Overview of Cancer Stem Cells (CSCs) and Mechanisms of their Regulation: Implications for Cancer Therapy. Curr Protoc Pharmacol 2013;14:Unit 14.25.
[24] Lee G, Hall RR 3rd, Ahmed AU. Cancer Stem Cells: Cellular Plasticity, Niche, and its Clinical Relevance. J Stem Cell Res Ther 2016;6:363.
[25] Kaminska K, Szczylik C, Bielecka ZF, Bartnik E, Porta C, Lian F, et al. The Role of the Cell-Cell Interactions in Cancer Progression. J Cell Mol Med 2015;19:283-96.
[26] Zhan HX, Zhou B, Cheng YG, Xu JW, Wang L, Zhang GY, et al. Crosstalk between Stromal Cells and Cancer Cells in Pancreatic Cancer: New Insights into Stromal Biology. Cancer Lett 2017;392:83-93.
[27] Conklin MW, Keely PJ. Why the Stroma Matters in Breast Cancer: Insights into Breast Cancer Patient Outcomes through the Examination of Stromal Biomarkers. Cell Adh Migr 2012;6:249-60.
[28] Ghajar CM, Peinado H, Mori H, Matei IR, Evason KJ, Brazier H, et al. The Perivascular Niche Regulates Breast Tumour Dormancy. Nat Cell Biol 2013;15:807-17.
[29] Oh M, Nor JE. The Perivascular Niche and Self-Renewal of Stem Cells. Front Physiol 2015;6:367.
[30] Allavena P, Sica A, Solinas G, Porta C, Mantovani A. The Inflammatory Micro-Environment in Tumor Progression: The Role of Tumor-Associated Macrophages. Crit Rev Oncol Hematol 2008;66:1-9.
[31] Borovski T, de Sousa EM, Vermeulen L, Medema JP. Cancer Stem Cell Niche: The Place To Be. Cancer Res 2011;71:634-9.
[32] Melzer C, von der Ohe J, Lehnert H, Ungefroren H, Hass R. Cancer Stem Cell Niche Models and Contribution by Mesenchymal Stroma/Stem Cells. Mol Cancer 2017;16:28.
[33] Shimoda M, Mellody KT, Orimo A. Carcinoma-Associated Fibroblasts Are a Rate-Limiting Determinant for Tumour Progression. Semin Cell Dev Biol 2010;21:19-25.
[34] Strell C, Rundqvist H, Ostman A. Fibroblasts-a Key Host Cell Type in Tumor Initiation, Progression, and Metastasis. Ups J Med Sci 2012;117:187-95.
[35] Korkaya H, Kim GI, Davis A, Malik F, Henry NL, Ithimakin S, et al. Activation of an IL6 Inflammatory Loop Mediates Trastuzumab Resistance in HER2+ Breast Cancer by Expanding the Cancer Stem Cell Population. Mol Cell 2012;47:570-84.
[36] Chen L, Fan J, Chen H, Meng Z, Chen Z, Wang P, et al. The IL-8/CXCR1 Axis is Associated with Cancer Stem Cell-Like Properties and Correlates with Clinical Prognosis in Human Pancreatic Cancer Cases. Sci Rep 2014;4:5911.
[37] Chen X, Liu L, Wang Y, Liu B, Zeng D, Jin Q, et al. Identification of Breast Cancer Recurrence Risk Factors Based on Functional Pathways in Tumor and Normal Tissues. Oncotarget 2017;8:20679-94.
[38] Thiery JP, Sleeman JP. Complex Networks Orchestrate Epithelial-Mesenchymal Transitions. Nat Rev Mol Cell Biol 2006;7:131-42.
[39] Mitra A, Mishra L, Li S. EMT, CTCs and CSCs in Tumor Relapse and Drug-Resistance. Oncotarget 2015;6:10697-711.
[40] Sainio A, Jarvelainen H. Extracellular Matrix Macromolecules: Potential Tools and Targets in Cancer Gene Therapy. Mol Cell Ther 2014;2:14.
[41] Plaks V, Kong N, Werb Z. The Cancer Stem Cell Niche: How Essential is the Niche in Regulating Stemness of Tumor Cells? Cell Stem Cell 2015;16:225-38.
[42] Giussani M, Merlino G, Cappelletti V, Tagliabue E, Daidone MG. Tumor-Extracellular Matrix Interactions: Identification of Tools Associated with Breast Cancer Progression. Semin Cancer Biol 2015;35:3-10.
[43] Trotter TN, Yang Y. Matricellular Proteins as Regulators of Cancer Metastasis to Bone. Matrix Biol 2016;52-54:301-14.